|
|
|
Volumn 84, Issue SUPPL. 1, 2001, Pages 1-2
|
|
Improving the standard of care in the management of cancer-related anaemia: Focus on darbepoetin alfa, a novel erythropoiesis stimulating protein: Introduction
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DARBEPOIETIN ALFA;
ERYTHROPOIETIN;
ERYTHROPOIETIN RECEPTOR;
GROWTH FACTOR;
HEMOGLOBIN;
IRON;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
RECOMBINANT ERYTHROPOIETIN;
SIALIC ACID;
UNCLASSIFIED DRUG;
DRUG DERIVATIVE;
RECOMBINANT PROTEIN;
ANEMIA;
CANCER;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG ACTIVITY;
DRUG HALF LIFE;
DRUG SAFETY;
DRUG TOLERABILITY;
EDITORIAL;
HUMAN;
PRIORITY JOURNAL;
QUALITY OF LIFE;
ARTICLE;
BLOOD;
DRUG SCREENING;
HALF LIFE TIME;
NEOPLASM;
ANEMIA;
CLINICAL TRIALS;
DRUG EVALUATION, PRECLINICAL;
ERYTHROPOIETIN;
HALF-LIFE;
HUMANS;
NEOPLASMS;
RECOMBINANT PROTEINS;
|
|
EID: 0035318753
PISSN: 00070920
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
|
Times cited : (4)
|
|
References (7)
|
